As illustrated by the example of everolimus for the treatment of TSC or cerliponase alfa for CLN2, precision medicine is typically single-target rather than multi-target, although multi-target approaches may be needed for genetic epilepsies with complex molecular mechanisms. This evidence concerns the gene TPP1 and tuberous sclerosis.